Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Real-time Estimate Cboe BZX  -  01:31:25 2023-01-30 pm EST
12.87 USD   -4.63%
01/11Transcript : Protagonist Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM
CI
01/06Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics Reports Granting of Inducement Award

11/16/2022 | 04:06pm EST

NEWARK, Calif., Nov. 16, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D., M.S., F.A.C.P., the Company's recently hired Chief Medical Officer, in accordance with the terms of Dr. Molina's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Dr. Molina received options to purchase 127,500 shares and restricted stock units (RSUs) to acquire 21,250 shares, respectively, of Protagonist Therapeutics common stock. The exercise price of the options is $8.04, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on November 15, 2022. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Dr. Molina's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to Dr. Molina's entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist Therapeutics

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 stage of development. The VERIFY (Phase 3) and REVIVE (Phase 2) studies of rusfertide in polycythemia vera are ongoing. Protagonist owns all marketing rights to rusfertide.

Protagonist has partnered with Janssen Biotech, Inc. on the development of PN-235 (JNJ-77242113) in moderate-to-severe psoriasis and inflammatory bowel disease. PN-235 is currently in multiple studies in psoriasis, led by Janssen.

Protagonist is headquartered in Newark, California. For more information on Protagonist, please visit the Company's website at www.protagonist-inc.com.

Protagonist Therapeutics, Inc.
 (PRNewsfoto/Protagonist Therapeutics Inc.)

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-granting-of-inducement-award-301680659.html

SOURCE Protagonist Therapeutics, Inc.


ę PRNewswire 2022
All news about PROTAGONIST THERAPEUTICS, INC.
01/11Transcript : Protagonist Therapeutics, Inc. Presents at 41st Annual J.P. Morg..
CI
01/06Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transit..
CI
2022Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
PR
2022Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology S..
PR
2022Protagonist Therapeutics Reports Granting of Inducement Award
PR
2022HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintain..
MT
2022PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
2022Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
2022Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations